Day: September 21, 2020

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESHALIFAX, Nova Scotia, Sept. 21, 2020 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a 2019 TSX Venture 50™ ranked company focused on the home health care industry, is pleased to announce that it has expanded operations in the South Central, U.S. region with the acquisition of an Arkansas home care business. The execution of the definitive agreement and related information pertaining to this acquisition was previously announced on September 8, 2020. All amounts are in United States dollars (“USD”) unless otherwise specified.   “This acquisition builds on the investment we made in the region a year ago when we entered Oklahoma,” said Chris Dobbin, President & CEO of Nova Leap. “We’re excited...

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today highlighted updated clinical data from the pivotal trial of envafolimab in MSI-H/dMMR cancer patients that were recently presented by the Company’s corporate partners, 3D Medicines and Alphamab Oncology.In a presentation highlighting updated clinical results at the Chinese Society of Clinical Oncology (CSCO) 2020 Virtual Scientific Program entitled, “Subcutaneous Injection of PD-L1 Antibody Envafolimab (KN035) in Advanced Tumors with Mismatch-Repair...

Information från Hövding Sverige AB (publ)Pressmeddelande, Malmö 2020-09-21Sista dag för handel med BTA i Hövding AB (publ)Sista dag för handel i bolagets betalda tecknade aktier, HOVD BTA, är den 24 september 2020.Information om betald tecknad aktie:Kortnamn: HOVD BTAISIN-kod: SE0014730248Sista handelsdag: 24 september 2020För ytterligare information, vänligen kontakta:Fredrik Carling, VD, Hövding Sverige AB (publ)Tel: 040 – 236 868fredrik.carling@hovding.seDenna informationInformationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 21 september 2020, kl. 14.00.Om Hövding Sverige ABHövding Sverige AB (publ) utvecklar, marknadsför och säljer “Hövding – Airbag for Urban Cyclists”. En revolutionerande cykelhjälm bestående av en krage innehållande en airbag som cyklisten bär kring halsen. Airbagen...

CHICAGO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Whole Earth Brands, Inc. (the “Company” or “Whole Earth Brands”) (Nasdaq: FREE), today announced the appointment of its Chief Executive Officer, Albert Manzone, to the Company’s board of directors (“Board of Directors” or “Board”), effective September 18, 2020. Following Mr. Manzone’s appointment, the Board of Directors will consist of seven members.Irwin Simon, Executive Chairman of Whole Earth Brands’ Board, commented, “Albert was instrumental in the formation of Whole Earth Brands through our business combination in June, and I am thrilled to welcome him to our Board of Directors. Albert brings a high level of strategic acuity, operational know-how, and a global mindset with over 30 years of accomplishments in the consumer products industry and at McKinsey & Co. His proven leadership...

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it received the final approximately $0.9 million in funding under the current grant from the Bill & Melinda Gates Foundation. The grant payment will support ongoing development activities for Daré’s investigational user-controlled, long-acting reversible contraceptive (UC-LARC), DARE-LARC1. Development of DARE-LARC1 has been supported by approximately $19.5 million in grant funding from the foundation prior to this most recent disbursement.The technology underpinning DARE-LARC1 is designed to store and precisely deliver therapeutic doses over months or years in a single implant and was originally developed at the Massachusetts Institute of Technology (MIT) by renowned researchers Robert...

EMERYVILLE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) — Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced the appointments of Caroline M. Loewy, Mary E. Stutts and Denelle J. Waynick to newly created seats on its Board of Directors, effective immediately. Zogenix’s Board now includes 10 members, nine of whom are independent.“We are delighted to welcome Ms. Loewy, Ms. Stutts and Ms. Waynick to our Board of Directors,” said Cam L. Garner, Chairman of the Board. “Their combined decades of experience in the biopharmaceutical industry and extensive knowledge in the areas of patient and rare disease advocacy, investor relations, corporate communications, public affairs, international operations, and legal affairs will prove invaluable to our team as Zogenix...

HAMILTON, Bermuda, Sept. 21, 2020 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways that are implicated across a spectrum of diseases, today announced that the company will host a virtual Rilonacept Analyst Day on Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. Eastern Daylight Time.The event will feature presentations from the Kiniksa management team on the market opportunity for rilonacept in recurrent pericarditis as well as the company’s continued commercial preparations and launch strategy. Additionally, guest speaker Paul Cremer, MD, Cardiovascular Medicine, Cleveland Clinic, will review the burden of recurrent pericarditis, the current treatment landscape, and the unmet need.Rilonacept...

WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 for the treatment of patients hospitalized with COVID-19. Pending FDA feedback, ARCA anticipates initiating the Phase 2b portion of a sequential Phase 2b/3 clinical evaluation of AB201 as early as the fourth quarter of this year.Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “This IND submission is a key milestone in the clinical development of AB201. With what we believe...

TORONTO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Jade Power Trust (“Jade Power” or the “Trust”) (TSXV:JPWR.UN) announces that the special committee comprised of certain independent directors of the administrator of the Trust (the “Committee”) struck to explore strategic alternatives for the Trust has been disbanded. The formation of the Committee was first announced by the Trust on May 15, 2020. Further, the Trust announces that it has terminated the mandate of the Trust’s financial advisor BAC IP EAD (BAC Securities) to support the evaluation of potential alternatives.J. Colter Eadie, Chief Executive Officer of Jade Power commented, “We thank the Committee members for their work during the tenure of the Committee’s mandate. As noted from our Q2 2020 financial results, the Trust has been achieving record energy generation and profit levels,...

BOCA RATON, Fla., Sept. 21, 2020 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT) announced today that, via its commercial channel (“ADT Commercial”), it is investing in Percepta Labs, an artificial-intelligence technology startup out of Philadelphia. ADT Commercial is a premier provider of commercial security, fire, life safety, and risk consulting services in the U.S., and through its investment will fund the commercialization and application of the startup’s cutting-edge AI technology to help detect and deter shoplifting. ADT Commercial will work directly with Percepta to further test and develop the application of Percepta’s proprietary, socially responsible AI technology in commercial environments and facilitate the launch when the solution is market-ready.Founded by Philippe Sawaya, Neil Gramopadhye, and Jonathan Mak while pursuing...